Herberman R B, Hiserodt J, Vujanovic N, Balch C, Lotzova E, Bolhuis R, Golub S, Lanier L L, Phillips J H, Riccardi C, Ritz J, Santoni A, Schmidt R E, Uchida A
Pittsburgh Cancer Institute and Departments of Medicine and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Department of General Surgery, MD Anderson Hospital and Tumor Institute, Houston, TX 77030, USA.
Immunol Today. 1987;8(6):178-81. doi: 10.1016/0167-5699(87)90035-1.
Leukocytes in blood and spleen can be activated by interleukin 2 (IL-2) to become cytotoxic to certain tumor cell lines in vitro. Recent evidence suggests that such lymphokine-activated killer (LAK) cells can bring about the regression of solid tumors in animals and patients, under certain circumstances. Here, Ronald Herberman and colleagues from eight international laboratories, review what is known of the characteristics of LAK cell activity and conclude that most of it can be attributed to natural killer cells stimulated by IL-2.
血液和脾脏中的白细胞可被白细胞介素2（IL-2）激活，从而在体外对某些肿瘤细胞系产生细胞毒性。最近的证据表明，在某些情况下，这种淋巴因子激活的杀伤（LAK）细胞可使动物和患者体内的实体瘤消退。在此，来自八个国际实验室的罗纳德·赫伯曼及其同事回顾了已知的LAK细胞活性特征，并得出结论：其大部分活性可归因于受IL-2刺激的自然杀伤细胞。
